RSSPsoriasis

Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential

Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential

| January 1, 2019

 J Clin Aesthet Dermatol. 2019;12(1):11–15 by James Q. Del Rosso, DO; Leon Kircik, MD; Tina Lin PharmD; and Radhakrishnan Pillai, PhD Dr. Del Rosso is with JDR Dermatology Research/Thomas Dermatology in Las Vegas, Nevada. Dr. Kircik is with the Indiana University School of Medicine in Indianapolis, Indiana; Physicians Skin Care, PLLC in Louisville, Kentucky; and […]

Continue Reading

Review of the Efficacy and Safety of Topical Mahonia aquifolium for the Treatment of Psoriasis and Atopic Dermatitis

Review of the Efficacy and Safety of Topical Mahonia aquifolium for the Treatment of Psoriasis and Atopic Dermatitis

| December 1, 2018

Emerging Authors in Dermatology The editors of JCAD are pleased to present this bi-annual column as a means to recognize select medical students, PhD candidates, and other young investigators in the field of dermatology for their efforts in scientific writing. We hope that the publication of their work encourages these and other emerging authors to […]

Continue Reading

Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream

Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream

| November 1, 2018

 J Clin Aesthet Dermatol. 2018;11(11):15–19 by Neal D. Bhatia, MD; David M. Pariser, MD; Leon Kircik, MD; Tina Lin, PharmD; Susan Harris, MS; Lindsey Mathew; and Radhakrishnan Pillai, PhD Dr. Bhatia is with Therapeutics Clinical Research in San Diego, California. Dr. Pariser is with Virginia Clinical Research, Inc. in Norfolk, Vriginia. Dr. Kircik is with […]

Continue Reading

Updates in  Psoriasis Management: Based on Selected Presentations from Maui Derm 2018

Updates in Psoriasis Management: Based on Selected Presentations from Maui Derm 2018

| October 1, 2018

J Clin Aesthet Dermatol 2018;11(10):S5–S23 A Message from the Guest Editor and MauiDerm Program Director   Dear Colleagues:  Each year, Maui Derm strives to bring to the podium the most up-to-date and cutting edge scientific and clinical developments in the field of dermatology. Maui Derm 2018 was no exception—our outstanding faculty delivered a mind-numbing amount of […]

Continue Reading

Updates in Psoriasis Management—October 2018 Digital Edition

Updates in Psoriasis Management—October 2018 Digital Edition

| October 1, 2018

Click the cover below to access the Updates in Psoriasis Management—October 2018 digital edition of JCAD!

Continue Reading

A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis

A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis

| June 1, 2018

by Olabola Awosika MD, MS; Misty G. Eleryan MD; Monica Rengifo-Pardo MD; Lindsay Doherty MS; Lisa W. Martin, MD; and Alison Ehrlich MD, MHS Drs. Awosika, Rengifo-Pardo, and Ehrlich are with the Department of Dermatology, The George Washington Medical Faculty Associates in Washington, DC. Dr. Martin is with the Department of Cardiology, The George Washington Medical […]

Continue Reading

An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis

An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis

| May 1, 2018

by Jerry Bagel, MD, MS, and Elise Nelson, LPN, CCRC Both authors are with the Psoriasis Treatment Center of Central New Jersey in East Windsor, New Jersey. J Clin Aesthet Dermatol. 2018;11(5):27–29 Funding: This study was sponsored by Taro Pharmaceuticals U.S.A., Inc. Disclosures: The authors have no conflicts of interest relevant to the content of […]

Continue Reading